← Eichor
Study identifier: NCT07115485 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Condition: Gastric or Gastroesophageal Junction Adenocarcinoma  ·  Sponsor: Shanghai Henlius Biotech

PhasePhase 2
Planned participants60
Who can joinAll sexes, 18 Days to 75 Days
Healthy volunteersNo

About this study

The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

This description comes directly from the study's public registry record.

Talk to the study team

Liya Wan  ·  86+13911662820  ·  Liya_Wan@henlius.com

Always discuss trial participation with your own doctor first.

Locations (1)

Beijing Cancer HospitalBeijing, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07115485